Recommend to a friend

HER2 mutations in metastatic NSCLC may be uncommon, but missing them can mean missing a critical treatment opportunity. In this activity, you’ll uncover how HER2 (ERBB2) alterations drive tumor growth and why they’re linked to poorer outcomes and brain metastases. Learn how to apply next-generation sequencing (NGS) to identify eligible patients and interpret results that guide targeted therapy decisions. Explore emerging treatments, including HER2-directed agents, and how they reshape care for this subset of patients. Real-world insights will help you bridge the gap between testing and treatment. If you’re treating lung cancer, this is one biomarker you can’t afford to overlook.